K. Van Abel

Mayo Clinic in Arizona

Papers

1

Total Citations

53

H-Index

1

About

Dr. K. Van Abel is a leading surgical oncologist whose research focuses on optimizing treatment for head and neck cancers, particularly human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Her most cited work, the Phase III MC1675 trial (53 citations), evaluates de-escalated adjuvant radiation therapy (DART) against standard treatment, aiming to reduce long-term toxicity while maintaining excellent oncologic outcomes for HPV-positive patients. This contribution is pivotal in the growing movement toward personalized, less morbid therapies for this distinct patient population. Beyond this landmark trial, Dr. Van Abel’s research spans surgical outcomes, quality of life, and novel therapeutic strategies in head and neck oncology. Her work has been instrumental in shaping evidence-based de-escalation protocols, directly impacting clinical guidelines and patient care. With a citation impact reflecting her influence in the field, Dr. Van Abel continues to advance the balance between cure and quality of life, making her a key voice in the evolution of head and neck cancer treatment.

Research Focus

Key Achievements

1
H-Index
1
Papers
53
Total Citations
53
Avg Citations/Paper
🏆 Most Cited Paper
MC1675, a Phase III Evaluation of De-Escalated Adjuvant Radiation Therapy (DART) vs. Standard Adjuvant Treatment for Human Papillomavirus Associated Oropharyngeal Squamous Cell Carcinoma
53 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 21
🏛 Institutions: Mayo Clinic in Arizona

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago